ReviewBiomedicines2022
Mixed-Phenotype Acute Leukemia: Clinical Diagnosis and Therapeutic Strategies.
Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 41 citations in OpenAlex.
- Immunophenotypic, Genetic, and Clinical Features Associated With RUNX1 Mutation in Acute Leukemias and Chronic Myeloid Neoplasms.International journal of laboratory hematology · 2026Article
- Outcomes of mixed phenotype acute leukemia undergoing allogeneic stem cell transplantation: a retrospective study of the ALWP of EBMT.Bone marrow transplantation · 2026Article
- Article
- Improved survival with fludarabine-based therapies in mixed phenotype acute leukaemia: A population-based study using the WHO 2022 classification.British journal of haematology · 2026Article
- Extreme hyperleukocytosis and blueberry muffin skin lesions as the initial presentation of neonatal leukemia: a case report.BMC pediatrics · 2026Article
- Article
- Article
- Efficacy and Long-Term Remission Following Haploidentical HSCT for Therapy-Related Acute Myelomonocytic Leukemia with Plasmacytoid Dendritic Cells Post-FCR Therapy for CLL: A Case Report.Journal of clinical medicine · 2026Article
- Immunophenotypically Defined Mixed-Phenotype Acute Leukemias: A Clinicopathologic Analysis of 52 Cases.EJHaem · 2026Article
- Diagnostic Ambiguity in BCR-ABL1-Positive MPAL in a Resource-Limited Setting: A Case Report.Case reports in hematology · 2026Article
- Mixed phenotype acute leukemia: 13 patients and a proposed management algorithm.Leukemia research reports · 2026Article
- Article
- Article
- Article
- Acute unilateral visual loss as a first presentation of mixed phenotype acute leukaemia.International journal of emergency medicine · 2025Article
- The Emergence of Subclones Following Initial Chemotherapy in Mixed Phenotype Acute Leukemia.Cureus · 2025Article
- Chemotherapy-free treatment of B-lymphoid/myeloid mixed phenotype acute leukemia: two case reports and literature review.Immunotherapy · 2025Review
- Menin Inhibitors: New Targeted Therapies for Specific Genetic Subtypes of Difficult-to-Treat Acute Leukemias.Cancers · 2025Review
- Flow cytometric characterisation of acute leukaemia in adolescent and adult Ethiopians.African journal of laboratory medicine · 2025Article
- Multiomic single cell sequencing identifies stemlike nature of mixed phenotype acute leukemia.Nature communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mixed-phenotype acute leukemia (MPAL) comprises a heterogenous group of leukemias that are genetically, immunophenotypically, and clinically, diverse. Given the rarity of the disease, the diagnosis and treatment of MPAL is extremely challenging. Recent collaborative efforts have made significant progress in understanding the complex genomic landscape of MPAL. Some retrospective studies support starting ALL-type induction followed by an allogeneic stem cell transplant(allo-sct) in the first complete remission; however, due to the inherent bias of retrospective data and small case series, a prospective validation of AML- and ALL-based regimen, and the incorporation of targeted therapies based on genetics and immunophenotype are warranted. The prognosis of adults and children with MPAL varies; this justifies modulating the intensity of therapy, including the use of allo-sct as a consolidation strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.